Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States

Abstract

Tiffany P Quock,1 Tingjian Yan,2 Ryan Tieu,2 Anita D’Souza,3 Michael S Broder21Medical Affairs, Prothena Biosciences Inc, South San Francisco, CA, USA; 2Health Services Research, Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA; 3Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USAPurpose: Cardiac dysfunction is common in amyloid light-chain (AL) amyloidosis, a rare disease caused by extracellular deposition of misfolded immunoglobulin light chains. This study aimed to examine economic/clinical disease burden in hospitalized cardiac amyloidosis patients.Patients and methods: Cardiac amyloidosis patients ≥18 years old hospitalized between 2014 and 2016 were identified in claims if they had ≥1 inpatient claim consistent with amyloidosis and evidence of cardiac dysfunction. Descriptive statistics were reported.Results: 3239 cardiac amyloidosis patients [1795 (55.4%) with concurrent renal disease] were identified. Mean (SD) length of stay was 8.3 (11.1) days. 25.2% were admitted to the intensive care unit. Mean overall hospitalization costs were USD$20,584. In-hospital mortality was 9.0% overall. 16.8% were readmitted within 30 days, with 11.2% dying in-hospital and a mean readmission cost of USD$18,536.Conclusion: Hospitalization for cardiac amyloidosis is costly, with high rates of readmission and mortality. Opportunities exist to improve care.Keywords: cardiac amyloidosis, hospitalization, burden of illness, cost

Keywords

• cardiac amyloidosis
• hospitalization
• burden of illness
• cost